For people with HIV and fatty liver on INSTI drugs, tesamorelin reduced liver fat by 31% compared to their starting point, which was a significant improvement. This finding is from the abstract summary - full study details were not available

Scientific Claim

In individuals with HIV and non-alcoholic fatty liver disease (NAFLD) taking integrase inhibitors (INSTIs), tesamorelin treatment led to a 31% relative reduction in hepatic fat fraction compared to baseline (p=0.006).

Original Statement

“the tesamorelin treated group saw a 31% relative reduction in HFF compared to baseline (p=0.006)”

From study:1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Evidence Quality Assessment

Claim Status

overstated

Study Design Support

Design supports claim

Appropriate Language Strength

probability

Can suggest probability/likelihood

Assessment Explanation

The study design allows causal inference but should use probability verbs; 'led to' should be 'may lead to'.

More Accurate Statement

“In individuals with HIV and non-alcoholic fatty liver disease (NAFLD) taking integrase inhibitors (INSTIs), tesamorelin treatment may lead to a 31% relative reduction in hepatic fat fraction compared to baseline (p=0.006).”

Evidence from Studies

Supporting (1)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Randomized Controlled Trial

Human

Contradicting (0)

No contradicting evidence found

Source Study

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Score: 63

DOI: 10.1093/ofid/ofad500.1334

Similar Assertions

For people with HIV and fatty liver on INSTI drugs, tesamorelin lowered liver fat by 4.9% compared to almost no change (0.1%) in the placebo group, which was a significant difference. This finding is from the abstract summary - full study details were not available

98%

For people with HIV and fatty liver on INSTI drugs, taking tesamorelin for a year likely reduces liver fat by 31% compared to their starting point, which is much better than the tiny change seen in those on a placebo.

96%

For people with HIV and fatty liver on INSTI drugs, taking tesamorelin for a year likely reduces liver fat by 4.9% compared to a tiny 0.1% reduction in those on a placebo.

95%

People with HIV and fatty liver disease on INSTI drugs who took tesamorelin for a year likely saw their liver fat decrease by 31% compared to their starting point.

95%

For people with HIV and fatty liver disease on integrase inhibitors, taking tesamorelin for a year likely reduced liver fat by almost 5%, while the placebo group saw almost no change.

94%